Clamp-625 is one of the top 10 brands of Dr. Reddy’s Laboratories, India. Clamp-625 is a combination medicine containing the semisynthetic antibiotic Amoxycillin and the β-lactamase inhibitor, Potassium clavulanate (β-lactamase is a type of enzyme produced by bacteria that resists Amoxycillin action).
Amoxycillin has a bactericidal effect. However, it is susceptible to hydrolysis by β-lactamases. Addition of clavulanic acid extends the antimicrobial spectrum and activity of amoxycillin.
β-lactamase resistance is an increasing problem that results in treatment failure in many common infections. Clamp-625 first overcomes the β-lactamase resistance, and then deals with the bacteria.
Clamp-625 is indicated in various bacterial infections like, Skin and Skin Structure Infections, Urinary Tract Infections, Upper Respiratory Tract Infections, Lower Respiratory Tract Infections.
Clamp-625 is manufactured by Dr. Reddy’s Laboratories (DRL), an Indian multinational pharmaceutical company based in Hyderabad, Telangana, India. The company has a state-of-the-art R&D Centre housing 70 laboratories with over 800 research scientists working on various projects. It works closely with other centres across the UK and the Netherlands, offering wide-ranging access to affordable and innovative medicines – from synthetic organic chemistry to formulations development; from intellectual property management to regulatory science; from polymorphism to bio-pharmaceutics.
Clamp-625 is an orally available combination antibiotic drug. The medicine contains two combinations. Amoxicillin is a penicillin type antibiotic which works by preventing bacteria from growing, and killing them. Clavulanic Acid when combined with penicillin-group antibiotics can overcome antibiotic resistance in bacteria, which otherwise inactivates most penicillin.
Bacterial Infections are caused by infectious bacteria which reproduce quickly in the body and may even give out toxins which can damage tissues and make you very ill.
Bacterial Infections differ from other infections due to the microbes that cause them. Even though less than one percent of bacteria can make humans sick, bacterial infections can range from minor illnesses such as sore throat and ear infections to more life-threatening conditions like meningitis and encephalitis.
Patients infected by bacteria have to be treated with antibiotics. Clamp-625 can be used to treat bacterial infections that may include:
Middle ear infection
Urinary tract infection
Clamp-625 has been known to work well among patients with various bacterial infections.
Patient w/ mononucleosis. Renal and hepatic impairment. Children. Pregnancy and lactation.
Monitoring Parameters- Periodically monitor renal, hepatic and haematologic function. Monitor for signs of anaphylaxis during 1st dose.
Hypersensitivity to penicillins. History of severe immediate hypersensitivity reaction to another β-lactam agent (e.g. cephalosporins, carbapenem or monobactam), history of cholestatic jaundice/hepatic dysfunction associated w/ amoxicillin and clavulanic acid therapy.
May increase plasma concentration of amoxicillin w/ probenecid. May increase allergic or hypersensitivity reaction w/ concomitant use of allopurinol and amoxicillin. May reduce efficacy of oral oestrogen/progesterone contraceptives.
Symptoms: GI symptoms, fluid and electrolyte imbalances; crystalluria and interstitial nephritis may lead to renal failure.
Management: Treat symptomatically w/ attention to water/electrolyte balance. May be removed by haemodialysis.
Mechanism of Action
Clavulanic acid has a high affinity for and binds to certain β-lactamases that generally inactivate amoxicillin by hydrolysing its β-lactam ring. Combining clavulanate K w/ amoxicillin extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other penicillins and cephalosporins.